Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 94

Sort by

Sort Order Select

Journal Articles

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Viola J.F. Strijbis, MSc, Ka Lei Cheung, Pavlina Konstantinova, PhD, Ying Poi Liu, PhD, Sander J van Deventer, MD PhD, Mettine H.A. Bos, PhD

Blood (2019) 134 (Supplement_1): 1110.

https://doi.org/10.1182/blood-2019-124120

Published: 2019

Journal Articles

The Combination of Marzeptacog Alfa (Activated) or Eptacog Alfa (Activated) with Emicizumab Appears Comparable As Assessed By the Thrombin Generation Test in Hemophilia a Plasma

Tom Knudsen, PhD DVM, Brajesh Kumar, Frank Del Greco, MBA, Linda Neuman, MD, Howard Levy, PhD MBBChir, Grant E. Blouse, PhD

Blood (2019) 134 (Supplement_1): 1112.

https://doi.org/10.1182/blood-2019-130559

Published: 2019

Journal Articles

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Patrick T. Ebbert, BS, Frederico Xavier, MD MS, Craig D. Seaman, MD MS, Margaret V. Ragni, MD MPH

Blood (2019) 134 (Supplement_1): 2416.

https://doi.org/10.1182/blood-2019-123198

Published: 2019

Journal Articles

Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO)

Jerzy Windyga, Pal A Holme, C. Hermans, Ana R Cid, Nirjhar Chatterjee, Hongyu Jiang, Viridiana Cano-Garcia, Carmen Escuriola

Blood (2019) 134 (Supplement_1): 2418.

https://doi.org/10.1182/blood-2019-124324

Published: 2019

Journal Articles

Thrombin Generation Assay in Plasma from Hemophilia a Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC

Marianne Kjalke, PhD, Mads Kjelgaard-Hansen, Søren Andersen, Ida Hilden

Blood (2019) 134 (Supplement_1): 3639.

https://doi.org/10.1182/blood-2019-122301

Published: 2019

Journal Articles

A Neutralizing Monoclonal Antibody (PF-06741086) Against Tissue Factor Pathway Inhibitor in Combination with Activated Prothrombin Complex Concentrate Increases Hemostasis in Inhibitor Hemophilia Plasmas without Excessive Thrombin Generation

Swapnil Rakhe, MS, Sheryl Bowley, PhD, John E. Murphy, PhD, Debra D Pittman, MS

Blood (2018) 132 (Supplement 1): 3779.

https://doi.org/10.1182/blood-2018-99-119831

Published: 2018

Journal Articles

Outcome of Immune Tolerance Induction Using an Extended Half-Life Clotting Factor Concentrate — Recombinant Factor VIII Fc (Eloctate™) — a Report from India

Aby Abraham, MD DM, Shashikant Apte, MD FRCPA, Chandrakala Shamukhaiah, MD DM, Fouzia N., DNB, DM, Kannan Subramaniam, DNB, DM, Akshata Rahate, MD DM, Abraham Sunder Singh, BSc, Aditi Joshi, BAMS, Kavitha M Lakshmi, MSc, Rajesh Phatale, MD, Shrimati Shetty, PhD, Sukesh Chandran Nair, MD, Biju George, DM, Vikram Mathews, MD, Alok Srivastava, MD, FRACP,FRCPA

Blood (2018) 132 (Supplement 1): 2494.

https://doi.org/10.1182/blood-2018-99-119279

Published: 2018

Journal Articles

Efficacy of Anti-TFPI Antibody PF-06741086 Alone and in Combination with Activated Prothrombin Complex Concentrates in Mouse Hemophilia a Bleeding Model

Amey Barakat, Reema Jasuja, PhD, John E. Murphy, PhD, Debra D Pittman, MS

Blood (2018) 132 (Supplement 1): 2460.

https://doi.org/10.1182/blood-2018-99-118431

Published: 2018

Journal Articles

A Novel Point-of-Care Whole Blood Coagulation Assay to Monitor Emicizumab Therapy in Patients with Hemophilia

Michael A Suster, PhD, Debnath Maji, M.Tech, Lalitha V. Nayak, MD, Christina Jenkins, MSN-PNP, RN, Susan Hunter, BSN, RN-BC, Alvin H. Schmaier, MD, Pedram Mohseni, PhD, Sanjay Ahuja

Blood (2018) 132 (Supplement 1): 2475.

https://doi.org/10.1182/blood-2018-99-113623

Published: 2018

Journal Articles

Assessment of a Novel Dielectric Microsensor for Monitoring Coagulation Factor Therapy in Children with Hemophilia with and without Inhibitors

Sanjay P Ahuja, MD, Michael A Suster, PhD, Debnath Maji, M.Tech, Ujjal Sekhon, BE, Janet Martin, BSN, RN-BC, Anirban Sen Gupta, PhD, Pedram Mohseni, PhD

Blood (2017) 130 (Supplement 1): 1062.

https://doi.org/10.1182/blood.V130.Suppl_1.1062.1062

Published: 2017

Journal Articles

"FEIBA Global Outcome Study (FEIBA GO)" Data Read-out: Real World Bleeding Frequency in Inhibitors Patients on Prophylaxis with APCC

C. Escuriola Ettingshausen, J. Windyga, MD, C. Hermans, MDMRCP,PhD, A.R. Cid, S. Rangarajan, A. Rocino, A. Gringeri, MD PhD, R. Crea, DVM, MSc

Blood (2017) 130 (Supplement 1): 4880.

https://doi.org/10.1182/blood.V130.Suppl_1.4880.4880

Published: 2017

Journal Articles

Observational Study of Recombinant Factor-VIII-Fc, Eloctate, in Hemophilia Patients with and without Inhibitors

Patrick T. Ebbert, BS, Margaret V. Ragni, MD MPH, Frederico Xavier, MD MS, Lynn M. Malec, MD, Craig D. Seaman

Blood (2017) 130 (Supplement 1): 3689.

https://doi.org/10.1182/blood.V130.Suppl_1.3689.3689

Published: 2017

Journal Articles

Elucidating the Excessive Pro-Coagulant Effect of a Sequence Identical Analogue to ACE910 in Combination with Bypassing Agents

Rudolf Hartmann, PhD, Tjerk Feenstra, MSc, Sabine Knappe, PhD, Michael Dockal, PhD, Friedrich Scheiflinger, PhD

Blood (2017) 130 (Supplement 1): 90.

https://doi.org/10.1182/blood.V130.Suppl_1.90.90

Published: 2017

Journal Articles

Rationale for and Design of a Tolerability and Safety Study of FEIBA Reconstituted in Regular or 50% Reduced Volume and Faster Infusion Rates in Patients with Hemophilia A or B with Inhibitors

Talaha Mubarak Ali, Naghmana Bajwa

Blood (2017) 130 (Supplement 1): 4886.

https://doi.org/10.1182/blood.V130.Suppl_1.4886.4886

Published: 2017

Journal Articles

Anticoagulant Actions of Recombinant Thrombomodulin and Activated Protein C and Their Neutralization By Factor VIII Inhibitor Bypass Activity (FEIBA)

Walter Jeske, Mary Lewis, Parul Aggarwal, Zafar Siddiqui, Omer Iqbal, Debra Hoppensteadt, PhD, Kazuhisa Tsuruta, Jawed Fareed, PhD, Sid Mehrota

Blood (2017) 130 (Supplement 1): 4905.

https://doi.org/10.1182/blood.V130.Suppl_1.4905.4905

Published: 2017

Journal Articles

Incidence of Thrombo-Embolic Events in Relation to Activated Prothrombin Complex Concentrate Exposure: A Literature Meta-Analysis

Matteo Rota, Paolo A Cortesi, Roberto Crea, DVM, MSc, Alessandro Gringeri, MD PhD, Lorenzo G Mantovani

Blood (2017) 130 (Supplement 1): 1077.

https://doi.org/10.1182/blood.V130.Suppl_1.1077.1077

Published: 2017

Journal Articles

Surgery in Patients with Factor VIII Inhibitors: A Retrospective Case Series at the Largest Canadian Hemophilia Care Centre

Aditi Khandelwal, MDM, Syed Mahamad, BSc candidate, Jerome M. Teitel, MD, Michelle Sholzberg, MDM, MSc

Blood (2016) 128 (22): 1418.

https://doi.org/10.1182/blood.V128.22.1418.1418

Published: 2016

Journal Articles

The Safety of Hemophilia Product Use: a Simulation Analysis

Stephanie Chiuve, ScD, Daniel Gallo, PhD, Christopher Rowan, PhD, Leonard A. Valentino, MD

Blood (2016) 128 (22): 5914.

https://doi.org/10.1182/blood.V128.22.5914.5914

Published: 2016

Journal Articles

A Novel Clot Waveform Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-Fixa/Fx Bispecific Antibody, Emicizumab

Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Yuka Tabuchi, Tetsuhiro Soeda, PhD, Nobuo Arai, Takehisa Kitazawa, Hidenari Takaoka, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2016) 128 (22): 1388.

https://doi.org/10.1182/blood.V128.22.1388.1388

Published: 2016

Journal Articles

Co-Administration of Factor XIII with Hemostatic Agents in Hemophilia Promotes Clot Stability and Composition

Joan D. Beckman, MDPhD, Lori A. Holle, PhD, Alisa S. Wolberg, PhD

Blood (2016) 128 (22): 2589.

https://doi.org/10.1182/blood.V128.22.2589.2589

Published: 2016

NARROW

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

The Combination of Marzeptacog Alfa (Activated) or Eptacog Alfa (Activated) with Emicizumab Appears Comparable As Assessed By the Thrombin Generation Test in Hemophilia a Plasma

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO)

Thrombin Generation Assay in Plasma from Hemophilia a Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC

A Neutralizing Monoclonal Antibody (PF-06741086) Against Tissue Factor Pathway Inhibitor in Combination with Activated Prothrombin Complex Concentrate Increases Hemostasis in Inhibitor Hemophilia Plasmas without Excessive Thrombin Generation

Outcome of Immune Tolerance Induction Using an Extended Half-Life Clotting Factor Concentrate — Recombinant Factor VIII Fc (Eloctate™) — a Report from India

Efficacy of Anti-TFPI Antibody PF-06741086 Alone and in Combination with Activated Prothrombin Complex Concentrates in Mouse Hemophilia a Bleeding Model

A Novel Point-of-Care Whole Blood Coagulation Assay to Monitor Emicizumab Therapy in Patients with Hemophilia

Assessment of a Novel Dielectric Microsensor for Monitoring Coagulation Factor Therapy in Children with Hemophilia with and without Inhibitors

"FEIBA Global Outcome Study (FEIBA GO)" Data Read-out: Real World Bleeding Frequency in Inhibitors Patients on Prophylaxis with APCC

Observational Study of Recombinant Factor-VIII-Fc, Eloctate, in Hemophilia Patients with and without Inhibitors

Elucidating the Excessive Pro-Coagulant Effect of a Sequence Identical Analogue to ACE910 in Combination with Bypassing Agents

Rationale for and Design of a Tolerability and Safety Study of FEIBA Reconstituted in Regular or 50% Reduced Volume and Faster Infusion Rates in Patients with Hemophilia A or B with Inhibitors

Anticoagulant Actions of Recombinant Thrombomodulin and Activated Protein C and Their Neutralization By Factor VIII Inhibitor Bypass Activity (FEIBA)

Incidence of Thrombo-Embolic Events in Relation to Activated Prothrombin Complex Concentrate Exposure: A Literature Meta-Analysis

Surgery in Patients with Factor VIII Inhibitors: A Retrospective Case Series at the Largest Canadian Hemophilia Care Centre

The Safety of Hemophilia Product Use: a Simulation Analysis

A Novel Clot Waveform Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-Fixa/Fx Bispecific Antibody, Emicizumab

Co-Administration of Factor XIII with Hemostatic Agents in Hemophilia Promotes Clot Stability and Composition

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only